NASA Awards $25 Million Single Award IDIQ Contract to Redwire
Will Advance Biotechnology and Support On-Orbit Operations Aboard ISS
A NASA single award, indefinite-delivery/indefinite-quantity (IDIQ) contract with a $25 million ceiling for a five-year period has been presented to Redwire to fulfill future task orders for biotechnology facilities, on-orbit operations support, mission integration, and related services for the agency on the International Space Station (ISS). Redwire will furnish these services to NASA when and if task orders are issued and there is no limit or minimum on the number of orders that may be issued.
"Redwire is grateful for NASA’s continued trust in our proven biotechnology capabilities and experience."
John Vellinger, Redwire
Under this contract, Redwire was recently issued a $2.5 million task order from NASA’s In Space Production Applications (InSPA) program to support additional drug development investigations on the ISS using Redwire’s PIL-BOX technology. The company will provide turnkey services to manage, integrate, and facilitate experiments and support on-orbit operations for NASA-funded research investigations aboard the ISS. Redwire’s capabilities are intended to support the diverse set life and materials investigations that NASA processes every year.
“Redwire’s biotechnology facilities have been an integral part of NASA’s ISS research strategy, supporting an increased throughput of critical scientific research and expanding on-orbit capabilities to accommodate cutting-edge science in drug development, cancer research, and tissue engineering,” said John Vellinger, president of Redwire In-Space Industries. “For this IDIQ contract, Redwire is grateful for NASA’s continued trust in our proven biotechnology capabilities and experience, and we are committed to enabling new discoveries for NASA and the ISS science community.”
Redwire has flown hundreds of experiments on both the Space Shuttle and the ISS. The company's microgravity technology enables space biotechnology and pharmaceutical development, helping companies unlock new insights for potential therapeutics and paving the way for microgravity research on future commercial space stations. Missions have included investigations for notable research partners including Bristol Myers Squibb, Eli Lilly and Company, and Butler University.
Redwire recently formed a new entity, SpaceMD, which will focus on growing seed crystals in orbit that will be used on Earth to create new and reformulated pharmaceuticals.